Anonymous ID: 62cf42 April 2, 2019, 11:58 a.m. No.6019984   🗄️.is đź”—kun   >>0020

>>6019921

my attitude towards that has changed since then. I don't care if that is what you want to do. Just do not force it on me or anyone else. Have heard a few things re: 54 too. Mind you I was too young to have even been there but those story's get passed around.

Anonymous ID: 62cf42 April 2, 2019, 12:09 p.m. No.6020108   🗄️.is đź”—kun   >>0121 >>0141 >>0219 >>0344

Motions to Dismiss Submitted by Sackler Family Members Named in Massachusetts Complaint

 

Attorneys for current and former directors of Purdue Pharma, including members of the Drs. Mortimer and Raymond Sackler families, have submitted Motions to Dismiss the misleading complaint filed against them by the Massachusetts Attorney General. These new court filings explain, for the first time, why the sensationalized portrayal of their conduct is untrue and misleading.

 

The Motions to Dismiss detail the distortions and mischaracterizations that riddle the amended complaint which overlooks the proper role of a Board of Directors in corporate governance. It does not allege any action at all by some of the directors, let alone any wrongful conduct, but drags them into the litigation anyway. We are confident the court will look past the inflammatory media coverage generated by the misleading complaint and apply the law fairly by dismissing all of these claims.

 

The same documents cited in the complaint in fact demonstrate that the Board of Directors was repeatedly advised that Purdue was fully complying with all of its legal and compliance obligations. Yet the complaint omits this crucial information by selectively editing out every reference to the many assurances of legal compliance that appear throughout Purdue management’s reports to the Board.

 

The family members have great sympathy for those suffering from addiction and are fully committed to contributing to solutions to the nation's complex crisis of opioid abuse. According to U.S. government data, the rise in opioid-related deaths is driven overwhelmingly by heroin and illicit fentanyl smuggled by drug traffickers into the U.S. from China and Mexico.

 

The documents cited by the complaint actually disprove many of its claims and omit important facts such as:

 

The Board did not respond to opioid abuse and the addiction crisis by trying to sell prescription opioids “harder” in 2018. In reality, a plan prepared by Purdue’s management (not the Board) proposed to substantially decrease calls to promote prescription opioids and showcased as the #1 product to be promoted a non-opioid medicine for constipation.

No member of the Board ever proposed, drafted, or supported a proposal known as Project Tango. In reality, Project Tango was a potential joint venture proposed by a third-party private equity firm, and the Board rejected the proposal.

No member of the Board of Directors ever asked Purdue to “fight back to convince doctors and patients to keep using the abuse deterrent formulation of OxyContin” in response to an insurance industry report – and the report at issue explicitly recognized that the abuse deterrent formulation of OxyContin had averted thousands of cases of abuse.

The complaint erroneously claims a Board member suggested that Purdue consider launching “yet another opioid.” In reality, he was proposing an abuse-deterrent formulation, which the FDA and Massachusetts have recognized is a valuable tool for reducing and preventing abuse.

 

The amended complaint’s consistent mischaracterizations are not just inaccuracies – they create a fundamentally false narrative about a complex public health crisis that distracts attention from the important effort of finding effective solutions that save lives.